JPMorgan Chase & Co. Acquires 43,470 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

JPMorgan Chase & Co. boosted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 103.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 85,545 shares of the biopharmaceutical company's stock after purchasing an additional 43,470 shares during the period. JPMorgan Chase & Co. owned 0.13% of Celldex Therapeutics worth $2,162,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Values First Advisors Inc. boosted its position in Celldex Therapeutics by 20.0% during the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 4,837 shares during the last quarter. Barclays PLC lifted its stake in shares of Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after purchasing an additional 76,207 shares during the last quarter. SG Americas Securities LLC increased its position in Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 4,967 shares during the last quarter. Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter worth about $2,867,000. Finally, Swiss National Bank raised its stake in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after acquiring an additional 1,400 shares in the last quarter.

Analysts Set New Price Targets

CLDX has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. Morgan Stanley assumed coverage on Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target for the company. UBS Group assumed coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $54.33.

Celldex Therapeutics Trading Down 0.1 %

NASDAQ:CLDX traded down $0.01 during mid-day trading on Friday, hitting $19.57. The company's stock had a trading volume of 377,561 shares, compared to its average volume of 882,887. The stock has a fifty day moving average of $19.21 and a 200-day moving average of $23.49. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -7.61 and a beta of 1.59. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. On average, equities analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.